beta TrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis
Elinor Dehan, Florian Bassermann, Daniele Guardavaccaro, Gaia Vasiliver-Shamis, Michael Cohen, Kym N Lowes, Michael Dustin, David CS Huang, Jack Taunton, Michele Pagano
Mol. Cell | CELL PRESS | Published : 2009
Awarded by National Institutes of Health
We thank M. McMahon, D. Ryoo, and J. Skaar for suggestions and for critically reading the manuscript; E. McIntush and Bethyl Laboratories for providing beta TrCP1 (BL726b) antibody; and I. Aifantis, J. Blenis, P. Bouillet, S. Buonamici, T. Cardozo, C. Lee, S. Fuchs, K. Kinnally, S. Korsmeyer L. Liebes, J. Maller, W. Pao, S. Valvo, and H.G. Wang for reagents and/or suggestions. M.P. is grateful to T.M. Thor for continuous support. This work was supported by a Department of Defense fellowship to E.D.; an American Association for Cancer Research (AACR) fellowship to F.B.; a fellowship from the America Italian Cancer Foundation and from Provincia di Benevento to D.G.; grants from the National Institutes of Health to M.P. (R01-GM57587, R37-CA76584, and R21-CA125173, M.L.D. (R01-A143542), and J.T. (GM071434); and an Australian National Health and Medical Research Council (NHMRC) Fellowship, an Australian NHMRC Program Grant, and a Leukemia and Lymphoma Society Specialized Center of Research (SCOR) grant (to D.C.S.H.). J.T. and M.P. are investigators with the Howard Hughes Medical Institute.